NCT02430363: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 |
|
|
| Unknown status | 2b | 58 | Europe, US, RoW | MK - 3475, Pembrolizumab, Keytruda, Suppressor of the PI3K/Akt pathways, Pictilisib, GDC-0941, BEZ235, NVP-BEZ235, Ipatasertib, GDC-0068 | Medical Research Council, Aarhus University Hospital, NCRI Clinical Studies Groups, ECCO - the European CanCer Organisation, Merck Sharp & Dohme LLC | Glioblastoma | 01/16 | 06/18 | | |
